Abstract
Background. Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome. Methods. Thirty-nine patients were identified between 1972 and 2006. Results. At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence. Conclusions. Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential.
| Original language | English |
|---|---|
| Pages (from-to) | 1607-1614 |
| Number of pages | 8 |
| Journal | Head and Neck |
| Volume | 30 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Esthesioneuroblastoma
- Head and neck neoplasms
- Olfactory neuroblastoma
- Radiotherapy
- Recurrence
- Surgery
- Survival
- Treatment
Fingerprint
Dive into the research topics of 'Esthesioneuroblastoma: The Princess Margaret Hospital experience'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver